Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E

Zismanov,Victoria; Attar‑Schneider,Oshrat; Lishner,Michael; Heffez Aizenfeld,Rachel; Tartakover Matalon,Shelly; Drucker,Liat

doi:10.3892/ijo.2014.2774

Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E

Authors:
- Victoria Zismanov
- Oshrat Attar‑Schneider
- Michael Lishner
- Rachel Heffez Aizenfeld
- Shelly Tartakover Matalon
- Liat Drucker
View Affiliations

Affiliations: Oncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel, Geriatric Department, Meir Medical Center, Kfar Saba, Israel
Published online on: November 24, 2014 https://doi.org/10.3892/ijo.2014.2774
Pages: 860-870

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intensive protein synthesis is a unique and differential trait of the multiple myeloma (MM) cells. Previously we showed that tetraspanin overexpression in MM cell lines attenuated mTOR and PI3K cascades, induced protein synthesis, activated unfolded protein response (UPR), and caused autophagic death, all suggesting breach of proteostasis. Here we assessed the role of translation initiation in the tetraspanin‑induced MM cell death with emphasis on eIF4E translation initiation factor. We showed tetraspanins attenuated peIF4E and its targets [c‑Myc, cyclin D1 (cycD1)]; eIF4E attenuation was Akt-dependent. eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti‑viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins. Furthermore, combined application of RBV and velcade had a synergistic anti‑MM effect. Our results demonstrate that breach of proteostasis via eIF4E inhibition is an attractive therapeutic approach that may be relatively easily achieved by employing RBV, making this strategy readily translatable into the clinic.

View Figures

View References

1	Anderson KC: Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol. 35(Suppl 1): S155–S162. 2007. View Article : Google Scholar
2	Pratt G: Molecular aspects of multiple myeloma. Mol Pathol. 55:273–283. 2002. View Article : Google Scholar : PubMed/NCBI
3	Agnelli L, Fabris S, Bicciato S, et al: Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol. 136:565–573. 2007. View Article : Google Scholar : PubMed/NCBI
4	Barnhart BC and Simon MC: Taking aim at translation for tumor therapy. J Clin Invest. 117:2385–2388. 2007. View Article : Google Scholar : PubMed/NCBI
5	Cenci S and Sitia R: Managing and exploiting stress in the antibody factory. FEBS Lett. 581:3652–3657. 2007. View Article : Google Scholar : PubMed/NCBI
6	Zismanov V, Lishner M, Tartakover-Matalon S, Radnay J, Shapiro H and Drucker L: Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer. 101:1402–1409. 2009. View Article : Google Scholar : PubMed/NCBI
7	Carrasco DR, Sukhdeo K, Protopopova M, et al: The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 11:349–360. 2007. View Article : Google Scholar : PubMed/NCBI
8	Patterson J, Palombella VJ, Fritz C and Normant E: IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol. 61:923–932. 2008. View Article : Google Scholar
9	Larsson O, Li S, Issaenko OA, et al: Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 67:6814–6824. 2007. View Article : Google Scholar : PubMed/NCBI
10	Wang X and Proud CG: Methods for studying signal-dependent regulation of translation factor activity. Methods Enzymol. 431:113–142. 2007. View Article : Google Scholar : PubMed/NCBI
11	Montanaro L and Pandolfi PP: Initiation of mRNA translation in oncogenesis: the role of eIF4E. Cell Cycle. 3:1387–1389. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wu KD, Zhou L, Burtrum D, Ludwig DL and Moore MA: Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother. 56:343–357. 2007. View Article : Google Scholar
13	Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC and Schneider RJ: eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol. 181:293–307. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA and Kittas C: Molecular aspects of multiple myeloma. Ann Oncol. 11:1217–1228. 2000. View Article : Google Scholar : PubMed/NCBI
15	Lin CJ, Cencic R, Mills JR, Robert F and Pelletier J: c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 68:5326–5334. 2008. View Article : Google Scholar : PubMed/NCBI
16	Drucker L, Tohami T, Tartakover-Matalon S, et al: Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis. 27:197–204. 2006. View Article : Google Scholar
17	Tohami T, Drucker L, Shapiro H, Radnay J and Lishner M: Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J. 21:691–699. 2007. View Article : Google Scholar : PubMed/NCBI
18	Lazo PA: Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 98:1666–1677. 2007. View Article : Google Scholar : PubMed/NCBI
19	Charrin S, le Naour F, Silvie O, Milhiet PE, Boucheix C and Rubinstein E: Lateral organization of membrane proteins: tetraspanins spin their web. Biochem J. 420:133–154. 2009. View Article : Google Scholar : PubMed/NCBI
20	Zismanov V, Drucker L, Attar-Schneider O, Matalon ST, Pasmanik-Chor M and Lishner M: Tetraspanins stimulate protein synthesis in myeloma cell lines. J Cell Biochem. 113:2500–2510. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lishner M, Zismanov V, Tohami T, Tartakover-Matalon S, Elis A and Drucker L: Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation. Cell Signal. 20:2309–2316. 2008. View Article : Google Scholar : PubMed/NCBI
22	Su DF, Xu LP, Miao CY, Xie HH, Shen FM and Jiang YY: Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats. Acta Pharmacol Sin. 25:148–151. 2004.PubMed/NCBI
23	Thiago LS, Perez-Andres M, Balanzategui A, et al: Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 99:155–162. 2014. View Article : Google Scholar :
24	Assouline S, Culjkovic B, Cocolakis E, et al: Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
25	Matassa DS, Amoroso MR, Agliarulo I, et al: Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. Cell Death Dis. 4:e8512013. View Article : Google Scholar : PubMed/NCBI
26	Issur M, Bougie I, Despins S and Bisaillon M: Enzymatic synthesis of RNAs capped with nucleotide analogues reveals the molecular basis for substrate selectivity of RNA capping enzyme: impacts on RNA metabolism. PLoS One. 8:e753102013. View Article : Google Scholar : PubMed/NCBI
27	Tan K, Culjkovic B, Amri A and Borden KL: Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun. 375:341–345. 2008. View Article : Google Scholar : PubMed/NCBI
28	Mujtaba T and Dou QP: Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 12:471–480. 2011.PubMed/NCBI
29	Moriya S, Che XF, Komatsu S, et al: Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol. 42:1541–1550. 2013.PubMed/NCBI
30	Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G and Lishner M: Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Invest. 92:178–190. 2012. View Article : Google Scholar
31	Graff JR and Zimmer SG: Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003. View Article : Google Scholar : PubMed/NCBI
32	Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M and Borden KL: eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR. J Cell Biol. 169:245–256. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wang X, Yue P, Chan CB, et al: Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol. 27:7405–7413. 2007. View Article : Google Scholar : PubMed/NCBI
34	Livingstone M, Larsson O, Sukarieh R, Pelletier J and Sonenberg N: A chemical genetic screen for mTOR pathway inhibitors based on 4E-BP-dependent nuclear accumulation of eIF4E. Chem Biol. 16:1240–1249. 2009. View Article : Google Scholar
35	Rong L, Livingstone M, Sukarieh R, et al: Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA. 14:1318–1327. 2008. View Article : Google Scholar : PubMed/NCBI
36	Saad H, Bellé R, Morales J, et al: Initiation factors eIF4: from sea urchin embryonic development to chronic lymphocytic leukemia. J Soc Biol. 201:307–315. 2007.(In French). View Article : Google Scholar
37	Saito Y, Tachibana I, Takeda Y, et al: Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res. 66:9557–9565. 2006. View Article : Google Scholar : PubMed/NCBI
38	Hasegawa M, Furuya M, Kasuya Y, et al: CD151 dynamics in carcinoma-stroma interaction: integrin expression, adhesion strength and proteolytic activity. Lab Invest. 87:882–892. 2007. View Article : Google Scholar : PubMed/NCBI
39	Maecker HT: Human CD81 directly enhances Th1 and Th2 cell activation, but preferentially induces proliferation of Th2 cells upon long-term stimulation. BMC Immunol. 4:12003. View Article : Google Scholar : PubMed/NCBI
40	Zöller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 9:40–55. 2009. View Article : Google Scholar
41	Jee BK, Park KM, Surendran S, et al: KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. Biochem Biophys Res Commun. 342:655–661. 2006. View Article : Google Scholar : PubMed/NCBI
42	Suzuki M, Tachibana I, Takeda Y, et al: Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation. J Immunol. 182:6485–6493. 2009. View Article : Google Scholar : PubMed/NCBI
43	Dua K, Williams TM and Beretta L: Translational control of the proteome: relevance to cancer. Proteomics. 1:1191–1199. 2001. View Article : Google Scholar : PubMed/NCBI
44	Jain MK and Zoellner C: Role of ribavirin in HCV treatment response: now and in the future. Expert Opin Pharmacother. 11:673–683. 2010. View Article : Google Scholar : PubMed/NCBI
45	Culjkovic B and Borden KL: Understanding and targeting the eukaryotic translation initiation factor eIF4E in head and neck cancer. J Oncol. 2009:9816792009. View Article : Google Scholar
46	Tamburini J, Green AS, Chapuis N, et al: Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle. 8:3893–3899. 2009. View Article : Google Scholar : PubMed/NCBI
47	Panfilio S, D’Urso P, Annechini G, et al: Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection. Leuk Res Rep. 2:39–40. 2013.PubMed/NCBI